Hu et al. [51] reported that increased VEGF levels at baseline were correlated with worse PFS in advanced non-small cell lung cancer treated with ICI, while Shibaki et al. [52] similarly observed a worse overall response rate to anti-PD-1 antibody treatment among fragile patients with advanced NSCLC and higher serum VEGF levels, thus reinforcing the hypothesis that increased VEGF levels may be predictive of reduced efficacy to these agents. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.